drugset / Trial / NCT06834165

Study Evaluating the Safety and Efficacy of Neffy or Intramuscular Adrenalin in Patients With Allergic Reactions After Oral Food Challenge or Allergen Immunotherapy

NCT06834165 ↗

Phase 4 Recruiting 600 enrolled ARS Pharmaceuticals, Inc.
RandomizedParallel-groupOpen-labelTreatment

Summary

The study is to assess the safety of neffy or IM Adrenalin in patients who are experiencing allergic reactions after an OFC, allergen Immunotherapy (AIT), or other allergy challenge that may require epinephrine intervention.

Timeline

Start
2025-05-20
Primary completion
2027-04
Completion
2027-06

Drugs

EvaluationDrugModalityDoseRoute
Comparator Epinephrine Other / unclassified — Intranasal

Indications